Solid Biosciences (NASDAQ:SLDB) Shares Gap Up on Earnings Beat

Solid Biosciences Inc. (NASDAQ:SLDB) shares gapped up before the market opened on Friday after the company announced better than expected quarterly earnings. The stock had previously closed at $7.12, but opened at $7.46. Solid Biosciences shares last traded at $7.2340, with a volume of 316,148 shares.

The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01.

Solid Biosciences News Summary

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Guggenheim started coverage with a Buy and a $26 price target (implies ~272% upside from recent levels), giving formal street-level momentum and a large upside case for the stock. Guggenheim starts coverage (Benzinga)
• Positive Sentiment: Needham reaffirmed Buy with a $19 price target, signaling continued analyst conviction in the company’s clinical progress and longer-term value. Needham reaffirms buy (Benzinga)
• Positive Sentiment: Chardan reaffirmed its Buy rating and $15 target, adding to the cluster of upgrade/reaffirmation headlines that can attract investor attention and trading demand. Chardan reaffirms buy (TickerReport)
• Positive Sentiment: Solid reported positive interim Phase 1/2 INSPIRE data for SGT-003 at the 2026 MDA meeting; the readout highlights generally favorable tolerability in 41 dosed participants—this is the primary fundamental catalyst supporting higher valuations. SGT-003 interim data (GlobeNewswire)
• Neutral Sentiment: The company issued its Q4 and full-year 2025 results and broader business updates; the release contains operational context and program timelines that investors will parse for runway and development plans. Q4 & full-year 2025 results (FinanzNachrichten)
• Negative Sentiment: SLDB missed Q4 EPS expectations (reported -$0.53 vs. consensus -$0.48), underlining ongoing losses and near-term profitability risk that likely capped the stock’s upside today. Earnings press release (Quartr)

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Chardan Capital reissued a “buy” rating and issued a $15.00 price target on shares of Solid Biosciences in a report on Friday. Citigroup reaffirmed a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Solid Biosciences in a research report on Friday. Guggenheim initiated coverage on shares of Solid Biosciences in a report on Friday. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, January 22nd. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Insider Activity at Solid Biosciences

In related news, insider Gabriel Brooks sold 28,335 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total transaction of $182,477.40. Following the completion of the transaction, the insider directly owned 96,708 shares of the company’s stock, valued at approximately $622,799.52. This represents a 22.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jessie Hanrahan sold 26,535 shares of Solid Biosciences stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $170,885.40. Following the completion of the sale, the insider directly owned 82,675 shares in the company, valued at approximately $532,427. The trade was a 24.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 597,672 shares of company stock valued at $3,816,546 in the last 90 days. 1.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Solid Biosciences

Several large investors have recently bought and sold shares of the business. Siren L.L.C. raised its stake in Solid Biosciences by 3.7% during the fourth quarter. Siren L.L.C. now owns 7,690,405 shares of the company’s stock valued at $43,374,000 after purchasing an additional 274,500 shares in the last quarter. Vestal Point Capital LP grew its stake in shares of Solid Biosciences by 95.5% in the 4th quarter. Vestal Point Capital LP now owns 5,815,000 shares of the company’s stock worth $32,797,000 after buying an additional 2,840,000 shares in the last quarter. Armistice Capital LLC increased its holdings in shares of Solid Biosciences by 179.1% in the 4th quarter. Armistice Capital LLC now owns 2,612,000 shares of the company’s stock worth $14,732,000 after buying an additional 1,676,000 shares during the last quarter. Nantahala Capital Management LLC increased its holdings in shares of Solid Biosciences by 505.4% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company’s stock worth $8,295,000 after buying an additional 1,421,968 shares during the last quarter. Finally, Alyeska Investment Group L.P. raised its position in Solid Biosciences by 2.6% during the third quarter. Alyeska Investment Group L.P. now owns 1,682,805 shares of the company’s stock valued at $10,383,000 after purchasing an additional 41,984 shares during the period. Institutional investors own 81.46% of the company’s stock.

Solid Biosciences Stock Performance

The stock has a market cap of $547.71 million, a PE ratio of -3.48 and a beta of 2.65. The stock has a fifty day moving average price of $6.43 and a 200 day moving average price of $5.80.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.